Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015, 37772-37776 [2014-15549]

Download as PDF 37772 Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices [USITC SE–14–023] Sunshine Act Meetings United States International Trade Commission. TIME AND DATE: July 11, 2014 at 11 a.m. PLACE: Room 101, 500 E Street SW., Washington, DC 20436, Telephone: (202) 205–2000. STATUS: Open to the public. MATTERS TO BE CONSIDERED: 1. Agendas for future meetings: None. 2. Minutes. 3. Ratification List. 4. Vote in Inv. Nos. 701–TA–515–521 and 731–TA–1251–1257 (Preliminary)(Certain Steel Nails from India, Korea, Malaysia, Oman, Taiwan, Turkey, and Vietnam). The Commission is currently scheduled to complete and file its determinations on July 14, 2014; views of the Commission are currently scheduled to be completed and filed on July 21, 2014. 5. Outstanding action jackets: None. In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting. AGENCY HOLDING THE MEETING: By order of the Commission: Issued: June 30, 2014. William R. Bishop, Supervisory Hearings and Information Officer. FOR FURTHER INFORMATION CONTACT: Erika Gehrmann, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (202) 598–6812. SUPPLEMENTARY INFORMATION: [FR Doc. 2014–15679 Filed 6–30–14; 4:15 pm] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Posting of Public Comments Drug Enforcement Administration [Docket No. DEA–393] Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015 Drug Enforcement Administration, Department of Justice. ACTION: Notice with request for comments. AGENCY: The Drug Enforcement Administration proposes to establish the 2015 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 17:49 Jul 01, 2014 Interested persons may file written comments on this notice in accordance with 21 CFR 1303.11(c) and 1315.11(d). Electronic comments must be submitted, and written comments must be postmarked, on or before August 1, 2014. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after midnight Eastern Time on the last day of the comment period. ADDRESSES: To ensure proper handling of comments, please reference ‘‘Docket No. DEA–393’’ on all electronic and written correspondence. The DEA encourages that all comments be submitted electronically through the Federal eRulemaking Portal which provides the ability to type short comments directly into the comment field on the Web page or attach a file for lengthier comments. Please go to http: //www.regulations.gov and follow the online instructions at that site for submitting comments. Paper comments that duplicate electronic submissions are not necessary. Should you, however, wish to submit written comments, in lieu of electronic comments, they should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: INTERNATIONAL TRADE COMMISSION Jkt 232001 Please note that all comments received in response to this docket are considered part of the public record and will be made available for public inspection online at http:// www.regulations.gov. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter. The Freedom of Information Act (FOIA) applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be made publicly available, you must include the phrase ‘‘PERSONAL IDENTIFYING INFORMATION’’ in the first paragraph of your comment. You must also place all the personal identifying information you do not want made publicly available in the first paragraph of your PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 comment and identify what information you want redacted. If you want to submit confidential business information as part of your comment, but do not want it to be made publicly available, you must include the phrase ‘‘CONFIDENTIAL BUSINESS INFORMATION’’ in the first paragraph of your comment. You must also prominently identify the confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments containing personal identifying information or confidential business information identified as directed above will be made publicly available in redacted form. An electronic copy of this document is available at http:// www.regulations.gov for easy reference. If you wish to personally inspect the comments and materials received or the supporting documentation the DEA used in preparing the proposed action, these materials will be available for public inspection by appointment. To arrange a viewing, please see the FOR FURTHER INFORMATION CONTACT paragraph above. Legal Authority Section 306 of the Controlled Substances Act (CSA), 21 U.S.C. 826, requires the Attorney General to determine the total quantity and establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. This responsibility has been delegated to the Administrator of the DEA pursuant to 28 CFR 0.100(b). The Administrator, in turn, has redelegated that authority to the Deputy Administrator, pursuant to 28 CFR part 0 subpart R, App. Analysis for Proposed 2015 Aggregate Production Quotas and Assessment of Annual Needs The proposed year 2015 aggregate production quotas and assessment of annual needs represent those quantities of schedule I and II controlled substances, and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured in the United States in 2015 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include E:\FR\FM\02JYN1.SGM 02JYN1 Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do not include imports of controlled substances necessary to provide for the medical, scientific, or other legitimate needs of the United States. In determining the proposed 2015 aggregate production quotas and assessment of annual needs, the DEA has taken into account the criteria that the DEA is required to consider in accordance with 21 U.S.C. 826(a), 21 CFR 1303.11 (aggregate production quotas for controlled substances), and 21 CFR 1315.11 (assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine). The DEA proposes the aggregate production quotas and assessment of annual needs for 2015 by considering: (1) Total net disposal of the class or chemical by all manufacturers and chemical importers during the current and two preceding years; (2) trends in the national rate of net disposal of the class or chemical; (3) total actual (or estimated) inventories of the class or chemical and of all substances manufactured from the class or chemical, and trends in inventory accumulation; (4) projected demand for such class or chemical as indicated by procurement and chemical import quotas requested in accordance with 21 CFR 1303.12, 1315.32, and 1315.34; and (5) other factors affecting the medical, scientific, research, and industrial needs in the United States, lawful export requirements, and reserve stocks, as the Deputy Administrator finds relevant. Other factors the DEA considered in calculating the aggregate production quotas, but not the assessment of annual needs, include product development requirements of both bulk and finished dosage form manufacturers, and other pertinent information. In determining the proposed 2015 assessment of annual needs, the DEA used the calculation methodology previously described in the 2010 and 2011 assessment of annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR 79407, Dec. 20, 2010, respectively). The DEA also specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, the DEA proposes to include in all schedule II aggregate production quotas, and certain schedule 37773 I aggregate production quotas (gammahydroxybutyric acid and tetrahydrocannabinols), an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The resulting established aggregate production quotas will reflect these included amounts. This action will not affect the ability of manufacturers to maintain inventory allowances as specified by regulation. The DEA expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need, as determined by the DEA. The DEA does not anticipate utilizing the reserve in the absence of these circumstances. The Deputy Administrator, therefore, proposes to establish the 2015 aggregate production quotas for the following schedule I and II controlled substances and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: Proposed established 2015 quotas (g) Basic class mstockstill on DSK4VPTVN1PROD with NOTICES Schedule I (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) ................................................................................... [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ..................................................................... 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) ....................................................................................................... 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) ................................................................................................... 1-(1-Phenylcyclohexyl)pyrrolidine ........................................................................................................................................................ 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ............................................................................................................................ 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ........................................................................................................................... 1-[1-(2-Thienyl)cyclohexyl]piperidine ................................................................................................................................................... 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) ............................................................................................................... 1-Butyl-3-(1-naphthoyl)indole (JWH-073) ............................................................................................................................................ 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) ........................................................................................... 1-Hexyl-3-(1-naphthoyl)indole (JWH-019) ........................................................................................................................................... 1-Methyl-4-phenyl-4-propionoxypiperidine ........................................................................................................................................... 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) ...................................................................................................................... 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) ............................................................................................................................ 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ........................................................................................................................ 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) ............................................................................................................................ 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) ........................................................................................................................... 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) .................................................................................................................... 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) ....................................................................................................................... 2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) ...................................................................................................................... 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ........................................................................................................................... 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ........................................................................................................................ 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) .......................................................................................................................... 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ....................................................................................................................................... 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ........................ 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ........................................................................................................................ 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ........................ 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) .............................................................................................................................. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) .................................. 2-(Methylamino)-1-phenylpentan-1-one (pentedrone) ......................................................................................................................... VerDate Mar<15>2010 17:49 Jul 01, 2014 Jkt 232001 PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 E:\FR\FM\02JYN1.SGM 02JYN1 15 15 15 15 10 45 45 15 45 45 45 45 2 45 45 45 45 45 45 45 30 30 30 30 30 15 30 15 30 15 15 37774 Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices Proposed established 2015 quotas (g) mstockstill on DSK4VPTVN1PROD with NOTICES Basic class 2,5-Dimethoxy-4-ethylamphetamine (DOET) ...................................................................................................................................... 2,5-Dimethoxy-4-n-propylthiophenethylamine ..................................................................................................................................... 2,5-Dimethoxyamphetamine ................................................................................................................................................................ 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ................................................................................................................ 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) .......................................................................................................... 3,4,5-Trimethoxyamphetamine ............................................................................................................................................................ 3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................ 3,4-Methylenedioxymethamphetamine (MDMA) ................................................................................................................................. 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ............................................................................................................................. 3,4-Methylenedioxy-N-methylcathinone (methylone) .......................................................................................................................... 3,4-Methylenedioxypyrovalerone (MDPV) ........................................................................................................................................... 3-Fluoro-N-methylcathinone (3-FMC) .................................................................................................................................................. 3-Methylfentanyl ................................................................................................................................................................................... 3-Methylthiofentanyl ............................................................................................................................................................................. 4-Bromo-2,5-dimethoxyamphetamine (DOB) ...................................................................................................................................... 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) .................................................................................................................................. 4-Fluoro-N-methylcathinone (4-FMC) .................................................................................................................................................. 4-Methoxyamphetamine ...................................................................................................................................................................... 4-Methyl-2,5-dimethoxyamphetamine (DOM) ...................................................................................................................................... 4-Methylaminorex ................................................................................................................................................................................ 4-Methyl-N-ethylcathinone (4-MEC) .................................................................................................................................................... 4-Methyl-N-methylcathinone (mephedrone) ........................................................................................................................................ 4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP) ........................................................................................................................ 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ......................................................................................................... 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ........................... 5-Methoxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... 5-Methoxy-N,N-diisopropyltryptamine .................................................................................................................................................. 5-Methoxy-N,N-dimethyltryptamine ..................................................................................................................................................... Acetyl-alpha-methylfentanyl ................................................................................................................................................................. Acetyldihydrocodeine ........................................................................................................................................................................... Acetylmethadol .................................................................................................................................................................................... Allylprodine .......................................................................................................................................................................................... Alphacetylmethadol .............................................................................................................................................................................. alpha-Ethyltryptamine .......................................................................................................................................................................... Alphameprodine ................................................................................................................................................................................... Alphamethadol ..................................................................................................................................................................................... alpha-Methylfentanyl ............................................................................................................................................................................ alpha-Methylthiofentanyl ...................................................................................................................................................................... alpha-Methyltryptamine (AMT) ............................................................................................................................................................ alpha-Pyrrolidinobutiophenone (a-PBP) .............................................................................................................................................. alpha-Pyrrolidinopentiophenone (a-PVP) ............................................................................................................................................ Aminorex .............................................................................................................................................................................................. Benzylmorphine ................................................................................................................................................................................... Betacetylmethadol ............................................................................................................................................................................... beta-Hydroxy-3-methylfentanyl ............................................................................................................................................................ beta-Hydroxyfentanyl ........................................................................................................................................................................... Betameprodine ..................................................................................................................................................................................... Betamethadol ....................................................................................................................................................................................... Betaprodine .......................................................................................................................................................................................... Bufotenine ............................................................................................................................................................................................ Cathinone ............................................................................................................................................................................................. Codeine methylbromide ....................................................................................................................................................................... Codeine-N-oxide .................................................................................................................................................................................. Desomorphine ...................................................................................................................................................................................... Diethyltryptamine ................................................................................................................................................................................. Difenoxin .............................................................................................................................................................................................. Dihydromorphine .................................................................................................................................................................................. Dimethyltryptamine .............................................................................................................................................................................. Dipipanone ........................................................................................................................................................................................... Fenethylline .......................................................................................................................................................................................... gamma-Hydroxybutyric acid ................................................................................................................................................................ Heroin .................................................................................................................................................................................................. Hydromorphinol .................................................................................................................................................................................... Hydroxypethidine ................................................................................................................................................................................. Ibogaine ............................................................................................................................................................................................... Lysergic acid diethylamide (LSD) ........................................................................................................................................................ Marihuana ............................................................................................................................................................................................ Mescaline ............................................................................................................................................................................................. Methaqualone ...................................................................................................................................................................................... Methcathinone ..................................................................................................................................................................................... Methyldesorphine ................................................................................................................................................................................. Methyldihydromorphine ........................................................................................................................................................................ VerDate Mar<15>2010 17:49 Jul 01, 2014 Jkt 232001 PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 E:\FR\FM\02JYN1.SGM 02JYN1 25 25 25 30 30 25 55 50 40 50 35 15 2 2 25 25 15 100 25 25 15 45 15 68 53 25 25 25 2 2 2 2 2 25 2 2 2 2 25 15 15 25 2 2 2 2 2 4 2 3 70 5 200 5 25 50 3,990,000 35 5 5 70,250,000 25 2 2 5 35 21,000 25 10 25 5 2 Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices 37775 Proposed established 2015 quotas (g) Basic class Morphine methylbromide ..................................................................................................................................................................... Morphine methylsulfonate .................................................................................................................................................................... Morphine-N-oxide ................................................................................................................................................................................ N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ........................................................................................................ N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) ..................................................... N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) .......................................... N,N-Dimethylamphetamine .................................................................................................................................................................. Naphthylpyrovalerone (naphyrone) ..................................................................................................................................................... N-Benzylpiperazine .............................................................................................................................................................................. N-Ethyl-1-phenylcyclohexylamine ........................................................................................................................................................ N-Ethylamphetamine ........................................................................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine ...................................................................................................................................... Noracymethadol ................................................................................................................................................................................... Norlevorphanol ..................................................................................................................................................................................... Normethadone ..................................................................................................................................................................................... Normorphine ........................................................................................................................................................................................ Phenomorphan .................................................................................................................................................................................... Psilocybin ............................................................................................................................................................................................. Psilocyn ................................................................................................................................................................................................ Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) ........................................................................ Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) ........................................................................................................ Tetrahydrocannabinols ........................................................................................................................................................................ Thiofentanyl ......................................................................................................................................................................................... Tilidine .................................................................................................................................................................................................. Trimeperidine ....................................................................................................................................................................................... 5 5 350 15 15 15 25 15 25 5 24 24 2 52 2 18 2 30 30 15 15 497,500 2 10 2 Schedule II mstockstill on DSK4VPTVN1PROD with NOTICES 1-Phenylcyclohexylamine .................................................................................................................................................................... 1-Piperidinocyclohexanecarbonitrile .................................................................................................................................................... 4-Anilino-N-phenethyl-4-piperidine (ANPP) ......................................................................................................................................... Alfentanil .............................................................................................................................................................................................. Alphaprodine ........................................................................................................................................................................................ Amobarbital .......................................................................................................................................................................................... Amphetamine (for conversion) ............................................................................................................................................................ Amphetamine (for sale) ....................................................................................................................................................................... Carfentanil ............................................................................................................................................................................................ Cocaine ................................................................................................................................................................................................ Codeine (for conversion) ..................................................................................................................................................................... Codeine (for sale) ................................................................................................................................................................................ Dextropropoxyphene ............................................................................................................................................................................ Dihydrocodeine .................................................................................................................................................................................... Diphenoxylate ...................................................................................................................................................................................... Ecgonine .............................................................................................................................................................................................. Ethylmorphine ...................................................................................................................................................................................... Fentanyl ............................................................................................................................................................................................... Glutethimide ......................................................................................................................................................................................... Hydrocodone (for conversion) ............................................................................................................................................................. Hydrocodone (for sale) ........................................................................................................................................................................ Hydromorphone ................................................................................................................................................................................... Isomethadone ...................................................................................................................................................................................... levo-Alphacetylmethadol (LAAM) ........................................................................................................................................................ Levomethorphan .................................................................................................................................................................................. Levorphanol ......................................................................................................................................................................................... Lisdexamfetamine ................................................................................................................................................................................ Meperidine ........................................................................................................................................................................................... Meperidine Intermediate-A .................................................................................................................................................................. Meperidine Intermediate-B .................................................................................................................................................................. Meperidine Intermediate-C .................................................................................................................................................................. Metazocine ........................................................................................................................................................................................... Methadone (for sale) ........................................................................................................................................................................... Methadone Intermediate ...................................................................................................................................................................... Methamphetamine ............................................................................................................................................................................... 5 5 2,687,500 17,625 3 25,125 21,875,000 37,500,000 19 240,000 50,000,000 46,125,000 19 101,375 1,337,500 174,375 3 2,108,750 3 137,500 99,625,000 6,250,000 5 4 5 3,375 29,750,000 6,250,000 6 11 6 19 31,875,000 34,375,000 2,061,375 [1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)]. Methylphenidate ................................................................................................................................................................................... Morphine (for conversion) .................................................................................................................................................................... Morphine (for sale) .............................................................................................................................................................................. Nabilone ............................................................................................................................................................................................... Noroxymorphone (for conversion) ....................................................................................................................................................... VerDate Mar<15>2010 17:49 Jul 01, 2014 Jkt 232001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\02JYN1.SGM 02JYN1 83,750,000 91,250,000 62,500,000 18,750 17,500,000 37776 Federal Register / Vol. 79, No. 127 / Wednesday, July 2, 2014 / Notices Proposed established 2015 quotas (g) Basic class Noroxymorphone (for sale) .................................................................................................................................................................. Opium (powder) ................................................................................................................................................................................... Opium (tincture) ................................................................................................................................................................................... Oripavine .............................................................................................................................................................................................. Oxycodone (for conversion) ................................................................................................................................................................ Oxycodone (for sale) ........................................................................................................................................................................... Oxymorphone (for conversion) ............................................................................................................................................................ Oxymorphone (for sale) ....................................................................................................................................................................... Pentobarbital ........................................................................................................................................................................................ Phenazocine ........................................................................................................................................................................................ Phencyclidine ....................................................................................................................................................................................... Phenmetrazine ..................................................................................................................................................................................... Phenylacetone ..................................................................................................................................................................................... Racemethorphan ................................................................................................................................................................................. Remifentanil ......................................................................................................................................................................................... Secobarbital ......................................................................................................................................................................................... Sufentanil ............................................................................................................................................................................................. Tapentadol ........................................................................................................................................................................................... Thebaine .............................................................................................................................................................................................. 1,475,000 112,500 687,500 22,750,000 8,350,000 137,500,000 21,875,000 7,750,000 35,000,000 6 19 3 9,375,000 3 3,750 215,003 6,255 12,500,000 125,000,000 List I Chemicals Ephedrine (for conversion) .................................................................................................................................................................. Ephedrine (for sale) ............................................................................................................................................................................. Phenylpropanolamine (for conversion) ................................................................................................................................................ Phenylpropanolamine (for sale) ........................................................................................................................................................... Pseudoephedrine (for conversion) ...................................................................................................................................................... Pseudoephedrine (for sale) ................................................................................................................................................................. The Deputy Administrator further proposes that aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Pursuant to 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Deputy Administrator may adjust the 2015 aggregate production quotas and assessment of annual needs as necessary. mstockstill on DSK4VPTVN1PROD with NOTICES Comments In accordance with 21 CFR 1303.11(c) and 1315.11(d), any interested person may submit written comments on or objections to these proposed determinations. Based on comments received in response to this notice, the Deputy Administrator may hold a public hearing on one or more issues raised. 21 CFR 1303.11(c) and 1515.11(e). In the event the Deputy Administrator decides to hold such a hearing, the Deputy Administrator will publish a notice of the hearing in the Federal Register. After consideration of any comments or objections, or after a hearing, if one is held, the Deputy Administrator will issue and publish in the Federal Register a final order establishing the 2015 aggregate production quota for each basic class of controlled substance and establishing the assessment of annual needs for the list I chemicals ephedrine, VerDate Mar<15>2010 17:49 Jul 01, 2014 Jkt 232001 pseudoephedrine, and phenylpropanolamine. 21 CFR 1303.11(c) and 1315.11(f). Dated: June 26, 2014. Thomas M. Harrigan, Deputy Administrator. [FR Doc. 2014–15549 Filed 7–1–14; 8:45 am] BILLING CODE 4410–09–P OFFICE OF MANAGEMENT AND BUDGET Draft 2014 Report to Congress on the Benefits and Costs of Federal Regulations and Unfunded Mandates on State, Local, and Tribal Entities Executive Office of the President, Office of Management and Budget. ACTION: Notice of availability and request for comments. AGENCY: The Office of Management and Budget (OMB) requests comments on its Draft 2014 Report to Congress on the Benefits and Costs of Federal Regulations, available at: http:// www.whitehouse.gov/omb/inforeg_ regpol_reports_congress/. The Draft Report is divided into two parts. Part I contains two chapters. Chapter I examines the benefits and costs of major Federal regulations issued in fiscal year 2013 and summarizes the benefits and costs of major regulations issued SUMMARY: PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 1,000,000 3,000,000 44,800,000 8,500,000 7,000 224,500,000 between October 2003 and September 2013. It also discusses regulatory impacts on State, local, and tribal governments, small business, wages, and economic growth. Chapter II offers recommendations for regulatory reform. Part II summarizes agency compliance with the Unfunded Mandates Reform Act. OMB requests that comments be submitted electronically to OMB by September 2, 2014 through www.regulations.gov. DATES: To ensure consideration of comments as OMB prepares this Draft Report for submission to Congress, comments must be in writing and received by September 2, 2014. ADDRESSES: Submit comments by one of the following methods: • www.regulations.gov: Direct comments to Docket ID OMB–2014– 0002 • Fax: (202) 395–7285 • Mail: Office of Information and Regulatory Affairs, Office of Management and Budget, Attn: Mabel Echols, NEOB, Room 10202, 725 17th Street NW., Washington, DC 20503. To ensure that your comments are received, we recommend that comments on this draft report be electronically submitted. All comments and recommendations submitted in response to this notice will be made available to the public, including by posting them on OMB’s Web site. For this reason, please do not E:\FR\FM\02JYN1.SGM 02JYN1

Agencies

[Federal Register Volume 79, Number 127 (Wednesday, July 2, 2014)]
[Notices]
[Pages 37772-37776]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-15549]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-393]


Proposed Aggregate Production Quotas for Schedule I and II 
Controlled Substances and Assessment of Annual Needs for the List I 
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Notice with request for comments.

-----------------------------------------------------------------------

SUMMARY: The Drug Enforcement Administration proposes to establish the 
2015 aggregate production quotas for controlled substances in schedules 
I and II of the Controlled Substances Act and assessment of annual 
needs for the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine.

DATES: Interested persons may file written comments on this notice in 
accordance with 21 CFR 1303.11(c) and 1315.11(d). Electronic comments 
must be submitted, and written comments must be postmarked, on or 
before August 1, 2014. Commenters should be aware that the electronic 
Federal Docket Management System will not accept comments after 
midnight Eastern Time on the last day of the comment period.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-393'' on all electronic and written correspondence. 
The DEA encourages that all comments be submitted electronically 
through the Federal eRulemaking Portal which provides the ability to 
type short comments directly into the comment field on the Web page or 
attach a file for lengthier comments. Please go to http://www.regulations.gov and follow the online instructions at that site for 
submitting comments. Paper comments that duplicate electronic 
submissions are not necessary. Should you, however, wish to submit 
written comments, in lieu of electronic comments, they should be sent 
via regular or express mail to: Drug Enforcement Administration, 
Attention: DEA Federal Register Representative/ODW, 8701 Morrissette 
Drive, Springfield, Virginia 22152.

FOR FURTHER INFORMATION CONTACT: Erika Gehrmann, Office of Diversion 
Control, Drug Enforcement Administration, 8701 Morrissette Drive, 
Springfield, Virginia 22152, Telephone: (202) 598-6812.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

    Please note that all comments received in response to this docket 
are considered part of the public record and will be made available for 
public inspection online at http://www.regulations.gov. Such 
information includes personal identifying information (such as your 
name, address, etc.) voluntarily submitted by the commenter.
    The Freedom of Information Act (FOIA) applies to all comments 
received. If you want to submit personal identifying information (such 
as your name, address, etc.) as part of your comment, but do not want 
it to be made publicly available, you must include the phrase 
``PERSONAL IDENTIFYING INFORMATION'' in the first paragraph of your 
comment. You must also place all the personal identifying information 
you do not want made publicly available in the first paragraph of your 
comment and identify what information you want redacted.
    If you want to submit confidential business information as part of 
your comment, but do not want it to be made publicly available, you 
must include the phrase ``CONFIDENTIAL BUSINESS INFORMATION'' in the 
first paragraph of your comment. You must also prominently identify the 
confidential business information to be redacted within the comment. If 
a comment has so much confidential business information that it cannot 
be effectively redacted, all or part of that comment may not be made 
publicly available. Comments containing personal identifying 
information or confidential business information identified as directed 
above will be made publicly available in redacted form.
    An electronic copy of this document is available at http://www.regulations.gov for easy reference. If you wish to personally 
inspect the comments and materials received or the supporting 
documentation the DEA used in preparing the proposed action, these 
materials will be available for public inspection by appointment. To 
arrange a viewing, please see the FOR FURTHER INFORMATION CONTACT 
paragraph above.

Legal Authority

    Section 306 of the Controlled Substances Act (CSA), 21 U.S.C. 826, 
requires the Attorney General to determine the total quantity and 
establish aggregate production quotas for each basic class of 
controlled substance listed in schedules I and II and for the list I 
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. This 
responsibility has been delegated to the Administrator of the DEA 
pursuant to 28 CFR 0.100(b). The Administrator, in turn, has 
redelegated that authority to the Deputy Administrator, pursuant to 28 
CFR part 0 subpart R, App.

Analysis for Proposed 2015 Aggregate Production Quotas and Assessment 
of Annual Needs

    The proposed year 2015 aggregate production quotas and assessment 
of annual needs represent those quantities of schedule I and II 
controlled substances, and the list I chemicals ephedrine, 
pseudoephedrine, and phenylpropanolamine, to be manufactured in the 
United States in 2015 to provide for the estimated medical, scientific, 
research, and industrial needs of the United States, lawful export 
requirements, and the establishment and maintenance of reserve stocks. 
These quotas include

[[Page 37773]]

imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do 
not include imports of controlled substances necessary to provide for 
the medical, scientific, or other legitimate needs of the United 
States.
    In determining the proposed 2015 aggregate production quotas and 
assessment of annual needs, the DEA has taken into account the criteria 
that the DEA is required to consider in accordance with 21 U.S.C. 
826(a), 21 CFR 1303.11 (aggregate production quotas for controlled 
substances), and 21 CFR 1315.11 (assessment of annual needs for 
ephedrine, pseudoephedrine, and phenylpropanolamine). The DEA proposes 
the aggregate production quotas and assessment of annual needs for 2015 
by considering: (1) Total net disposal of the class or chemical by all 
manufacturers and chemical importers during the current and two 
preceding years; (2) trends in the national rate of net disposal of the 
class or chemical; (3) total actual (or estimated) inventories of the 
class or chemical and of all substances manufactured from the class or 
chemical, and trends in inventory accumulation; (4) projected demand 
for such class or chemical as indicated by procurement and chemical 
import quotas requested in accordance with 21 CFR 1303.12, 1315.32, and 
1315.34; and (5) other factors affecting the medical, scientific, 
research, and industrial needs in the United States, lawful export 
requirements, and reserve stocks, as the Deputy Administrator finds 
relevant. Other factors the DEA considered in calculating the aggregate 
production quotas, but not the assessment of annual needs, include 
product development requirements of both bulk and finished dosage form 
manufacturers, and other pertinent information. In determining the 
proposed 2015 assessment of annual needs, the DEA used the calculation 
methodology previously described in the 2010 and 2011 assessment of 
annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR 79407, Dec. 20, 
2010, respectively).
    The DEA also specifically considered that inventory allowances 
granted to individual manufacturers may not always result in the 
availability of sufficient quantities to maintain an adequate reserve 
stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. 
This would be concerning if a natural disaster or other unforeseen 
event resulted in substantial disruption to the amount of controlled 
substances available to provide for legitimate public need. As such, 
the DEA proposes to include in all schedule II aggregate production 
quotas, and certain schedule I aggregate production quotas (gamma-
hydroxybutyric acid and tetrahydrocannabinols), an additional 25% of 
the estimated medical, scientific, and research needs as part of the 
amount necessary to ensure the establishment and maintenance of reserve 
stocks. The resulting established aggregate production quotas will 
reflect these included amounts. This action will not affect the ability 
of manufacturers to maintain inventory allowances as specified by 
regulation. The DEA expects that maintaining this reserve in certain 
established aggregate production quotas will mitigate adverse public 
effects if an unforeseen event resulted in substantial disruption to 
the amount of controlled substances available to provide for legitimate 
public need, as determined by the DEA. The DEA does not anticipate 
utilizing the reserve in the absence of these circumstances.
    The Deputy Administrator, therefore, proposes to establish the 2015 
aggregate production quotas for the following schedule I and II 
controlled substances and assessment of annual needs for the list I 
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, 
expressed in grams of anhydrous acid or base, as follows:

------------------------------------------------------------------------
                                                             Proposed
                                                            established
                       Basic class                          2015 quotas
                                                                (g)
------------------------------------------------------------------------
                               Schedule I
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-                                     15
 tetramethylcyclopropyl)methanone (UR-144)..............
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-                          15
 tetramethylcyclopropyl)methanone (XLR11)...............
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one                   15
 (butylone).............................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one                  15
 (pentylone)............................................
1-(1-Phenylcyclohexyl)pyrrolidine.......................              10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201).......              45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)......              45
1-[1-(2-Thienyl)cyclohexyl]piperidine...................              15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-                45
 200)...................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073).................              45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18              45
 and RCS-8).............................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019).................              45
1-Methyl-4-phenyl-4-propionoxypiperidine................               2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)......              45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).......              45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)......              45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398).......              45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122).......              45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4)...              45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081).....              45
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P).....              30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)........              30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).......              30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N).......              30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)................              30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-                                 15
 methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B;
 Cimbi-36)..............................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).......              30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-                                15
 methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C;
 Cimbi-82)..............................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I).........              30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-                                  15
 methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
 Cimbi-5)...............................................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone).......              15

[[Page 37774]]

 
2,5-Dimethoxy-4-ethylamphetamine (DOET).................              25
2,5-Dimethoxy-4-n-propylthiophenethylamine..............              25
2,5-Dimethoxyamphetamine................................              25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)              30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-              30
 T-4)...................................................
3,4,5-Trimethoxyamphetamine.............................              25
3,4-Methylenedioxyamphetamine (MDA).....................              55
3,4-Methylenedioxymethamphetamine (MDMA)................              50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)............              40
3,4-Methylenedioxy-N-methylcathinone (methylone)........              50
3,4-Methylenedioxypyrovalerone (MDPV)...................              35
3-Fluoro-N-methylcathinone (3-FMC)......................              15
3-Methylfentanyl........................................               2
3-Methylthiofentanyl....................................               2
4-Bromo-2,5-dimethoxyamphetamine (DOB)..................              25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)..............              25
4-Fluoro-N-methylcathinone (4-FMC)......................              15
4-Methoxyamphetamine....................................             100
4-Methyl-2,5-dimethoxyamphetamine (DOM).................              25
4-Methylaminorex........................................              25
4-Methyl-N-ethylcathinone (4-MEC).......................              15
4-Methyl-N-methylcathinone (mephedrone).................              45
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP).......              15
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-               68
 phenol.................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-                53
 phenol (cannabicyclohexanol or CP-47,497 C8-homolog)...
5-Methoxy-3,4-methylenedioxyamphetamine.................              25
5-Methoxy-N,N-diisopropyltryptamine.....................              25
5-Methoxy-N,N-dimethyltryptamine........................              25
Acetyl-alpha-methylfentanyl.............................               2
Acetyldihydrocodeine....................................               2
Acetylmethadol..........................................               2
Allylprodine............................................               2
Alphacetylmethadol......................................               2
alpha-Ethyltryptamine...................................              25
Alphameprodine..........................................               2
Alphamethadol...........................................               2
alpha-Methylfentanyl....................................               2
alpha-Methylthiofentanyl................................               2
alpha-Methyltryptamine (AMT)............................              25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP).............              15
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)............              15
Aminorex................................................              25
Benzylmorphine..........................................               2
Betacetylmethadol.......................................               2
beta-Hydroxy-3-methylfentanyl...........................               2
beta-Hydroxyfentanyl....................................               2
Betameprodine...........................................               2
Betamethadol............................................               4
Betaprodine.............................................               2
Bufotenine..............................................               3
Cathinone...............................................              70
Codeine methylbromide...................................               5
Codeine-N-oxide.........................................             200
Desomorphine............................................               5
Diethyltryptamine.......................................              25
Difenoxin...............................................              50
Dihydromorphine.........................................       3,990,000
Dimethyltryptamine......................................              35
Dipipanone..............................................               5
Fenethylline............................................               5
gamma-Hydroxybutyric acid...............................      70,250,000
Heroin..................................................              25
Hydromorphinol..........................................               2
Hydroxypethidine........................................               2
Ibogaine................................................               5
Lysergic acid diethylamide (LSD)........................              35
Marihuana...............................................          21,000
Mescaline...............................................              25
Methaqualone............................................              10
Methcathinone...........................................              25
Methyldesorphine........................................               5
Methyldihydromorphine...................................               2

[[Page 37775]]

 
Morphine methylbromide..................................               5
Morphine methylsulfonate................................               5
Morphine-N-oxide........................................             350
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide                    15
 (AKB48)................................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-                 15
 indazole-3-carboxamide (ADB-PINACA)....................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-              15
 1H-indazole-3-carboxamide (AB-FUBINACA)................
N,N-Dimethylamphetamine.................................              25
Naphthylpyrovalerone (naphyrone)........................              15
N-Benzylpiperazine......................................              25
N-Ethyl-1-phenylcyclohexylamine.........................               5
N-Ethylamphetamine......................................              24
N-Hydroxy-3,4-methylenedioxyamphetamine.................              24
Noracymethadol..........................................               2
Norlevorphanol..........................................              52
Normethadone............................................               2
Normorphine.............................................              18
Phenomorphan............................................               2
Psilocybin..............................................              30
Psilocyn................................................              30
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate              15
 (5-fluoro-PB-22; 5F-PB-22).............................
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22;                15
 QUPIC).................................................
Tetrahydrocannabinols...................................         497,500
Thiofentanyl............................................               2
Tilidine................................................              10
Trimeperidine...........................................               2
------------------------------------------------------------------------
                               Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine.................................               5
1-Piperidinocyclohexanecarbonitrile.....................               5
4-Anilino-N-phenethyl-4-piperidine (ANPP)...............       2,687,500
Alfentanil..............................................          17,625
Alphaprodine............................................               3
Amobarbital.............................................          25,125
Amphetamine (for conversion)............................      21,875,000
Amphetamine (for sale)..................................      37,500,000
Carfentanil.............................................              19
Cocaine.................................................         240,000
Codeine (for conversion)................................      50,000,000
Codeine (for sale)......................................      46,125,000
Dextropropoxyphene......................................              19
Dihydrocodeine..........................................         101,375
Diphenoxylate...........................................       1,337,500
Ecgonine................................................         174,375
Ethylmorphine...........................................               3
Fentanyl................................................       2,108,750
Glutethimide............................................               3
Hydrocodone (for conversion)............................         137,500
Hydrocodone (for sale)..................................      99,625,000
Hydromorphone...........................................       6,250,000
Isomethadone............................................               5
levo-Alphacetylmethadol (LAAM)..........................               4
Levomethorphan..........................................               5
Levorphanol.............................................           3,375
Lisdexamfetamine........................................      29,750,000
Meperidine..............................................       6,250,000
Meperidine Intermediate-A...............................               6
Meperidine Intermediate-B...............................              11
Meperidine Intermediate-C...............................               6
Metazocine..............................................              19
Methadone (for sale)....................................      31,875,000
Methadone Intermediate..................................      34,375,000
Methamphetamine.........................................       2,061,375
------------------------------------------------------------------------
  [1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
 non-prescription product; 750,000 grams for methamphetamine mostly for
       conversion to a schedule III product; and 61,375 grams for
                      methamphetamine (for sale)].
------------------------------------------------------------------------
Methylphenidate.........................................      83,750,000
Morphine (for conversion)...............................      91,250,000
Morphine (for sale).....................................      62,500,000
Nabilone................................................          18,750
Noroxymorphone (for conversion).........................      17,500,000

[[Page 37776]]

 
Noroxymorphone (for sale)...............................       1,475,000
Opium (powder)..........................................         112,500
Opium (tincture)........................................         687,500
Oripavine...............................................      22,750,000
Oxycodone (for conversion)..............................       8,350,000
Oxycodone (for sale)....................................     137,500,000
Oxymorphone (for conversion)............................      21,875,000
Oxymorphone (for sale)..................................       7,750,000
Pentobarbital...........................................      35,000,000
Phenazocine.............................................               6
Phencyclidine...........................................              19
Phenmetrazine...........................................               3
Phenylacetone...........................................       9,375,000
Racemethorphan..........................................               3
Remifentanil............................................           3,750
Secobarbital............................................         215,003
Sufentanil..............................................           6,255
Tapentadol..............................................      12,500,000
Thebaine................................................     125,000,000
------------------------------------------------------------------------
                            List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)..............................       1,000,000
Ephedrine (for sale)....................................       3,000,000
Phenylpropanolamine (for conversion)....................      44,800,000
Phenylpropanolamine (for sale)..........................       8,500,000
Pseudoephedrine (for conversion)........................           7,000
Pseudoephedrine (for sale)..............................     224,500,000
------------------------------------------------------------------------

    The Deputy Administrator further proposes that aggregate production 
quotas for all other schedule I and II controlled substances included 
in 21 CFR 1308.11 and 1308.12 remain at zero. Pursuant to 21 CFR 
1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, 
the Deputy Administrator may adjust the 2015 aggregate production 
quotas and assessment of annual needs as necessary.

Comments

    In accordance with 21 CFR 1303.11(c) and 1315.11(d), any interested 
person may submit written comments on or objections to these proposed 
determinations. Based on comments received in response to this notice, 
the Deputy Administrator may hold a public hearing on one or more 
issues raised. 21 CFR 1303.11(c) and 1515.11(e). In the event the 
Deputy Administrator decides to hold such a hearing, the Deputy 
Administrator will publish a notice of the hearing in the Federal 
Register. After consideration of any comments or objections, or after a 
hearing, if one is held, the Deputy Administrator will issue and 
publish in the Federal Register a final order establishing the 2015 
aggregate production quota for each basic class of controlled substance 
and establishing the assessment of annual needs for the list I 
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. 21 CFR 
1303.11(c) and 1315.11(f).

    Dated: June 26, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014-15549 Filed 7-1-14; 8:45 am]
BILLING CODE 4410-09-P